Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/8/2024 | $86.00 | Buy | Redburn Atlantic |
| 6/17/2024 | $88.00 | Buy | Truist |
| 5/24/2024 | $86.00 → $73.00 | Buy | H.C. Wainwright |
| 5/23/2024 | $60.00 | Buy | Deutsche Bank |
| 4/17/2024 | $65.00 | Sector Perform → Sector Outperform | Scotiabank |
| 4/3/2024 | $82.00 | Overweight | Cantor Fitzgerald |
| 3/13/2024 | $86.00 | Outperform | Raymond James |
| 12/19/2023 | Sector Perform | Scotiabank |
SOMERSET, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Alan Bash as the Company's President of CARVYKTI®. In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing Legend Biotech's commercial, technical operations, and quality functions of the franchise. "This expansion in our leadership structure is on the heels of CARVYKTI's recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion," said Ying Huang, Ph.D., Chief Executive Officer of Leg
SOMERSET, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), announced it is establishing a new, state-of-the-art research and development (R&D) facility in Philadelphia, Pennsylvania, to advance its portfolio of next-generation cell therapies. "This new facility underscores Legend's commitment to R&D, as we make key investments that will advance our pipeline and strengthen our leadership position in cell therapy innovation," said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. "We are excited to join the Philadelphia biotech community, a growing innovation hub and a prime location to attract top talent and strengthen our partn
SOMERSET, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Peter Salovey, Ph.D., President Emeritus of Yale University, to its Board of Directors. Dr. Salovey will serve as an independent director, effective August 9. "We are pleased to welcome Dr. Salovey to the Legend Board," said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. "Dr. Salovey's deep experience and wealth of knowledge in medical research and public health will be invaluable to Legend and offer a new and diverse perspective. We look forward to his insights and contributions to the strategic dec